Business and Organization (Details)	Apr. 12, 2019 USD ($) day	Sep. 12, 2019 USD ($) business_day day $ / shares
Castle Creek Pharmaceuticals, LLC | Castle Creek Pharmaceuticals, LLC Co-Development And License Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Maximum development costs payable by other party	$ 20,000,000
Excess costs payable by other party (percent)	70.00%
Excess costs payable (percent)	30.00%
Upfront payment received	$ 7,500,000
First milestone payment receivable	2,500,000
Second milestone payment receivable	30,000,000
Maximum sales milestone payments receivable	75,000,000
First sales milestone payment receivable	25,000,000
First product sales threshold for sales milestone payments	250,000,000
Second sales milestone receivable	50,000,000
Second product sales threshold for sales milestone payments	$ 750,000,000
Gross profit receivable from other party (percent of product sales)	30.00%
Payments due to third party	50.00%
Term of arrangement (years)	40 years
Days written notice required to terminate (days) | day	180
Gross profit owed in event of termination (percentage)	5.00%
Intrexon Corporation | Exclusive Channel Collaboration Agreement | Castle Creek Pharmaceuticals, LLC Co-Development And License Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments due to third party	50.00%
Fibrocell Science, Inc. | Castle Creek Pharmaceutical Holdings
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Merger share price (USD per share) | $ / shares		$ 3.00
Terms of merger, Company warrants, threshold days after Effective Time (days) | day		30
Terms of merger, threshold business days to adopt Merger Agreement after receipt of written request | business_day		5
Terms of merger, threshold holders of outstanding shares who have exercised or purported to exercise statutory appraisal rights		8.00%
Terms of merger, merger termination fee		$ 2,000,000.0